# Aligos (ALGS) — News

ALGS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/algs/news

## Recent headlines

- [Aligos Therapeutics - eligible for up to $420 mln in milestones and tiered royalties](https://www.ainvest.com/news/aligos-therapeutics-eligible-420-mln-milestones-tiered-royalties-2607) — AInvest Wire, Jul 6, 2026
  Aligos Therapeutics (NASDAQ: ALGS) has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B virus (HBV) infection. Under the terms of the agreement, Aligos will…
- [Aligos Therapeutics receives upfront payment of $25M USD from the exclusive license deal of Pevifoscorvir Sodium in Greater China for chronic hepatitis B virus infection](https://www.ainvest.com/news/aligos-therapeutics-receives-upfront-payment-25m-usd-exclusive-license-deal-pevifoscorvir-sodium-greater-china-chronic-hepatitis-virus-infection-2607) — AInvest Wire, Jul 6, 2026
  Aligos Therapeutics (NASDAQ: ALGS) has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B virus (HBV) infection. Under the terms of the agreement, Aligos will…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).